Alector logo

AlectorNASDAQ: ALEC

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

07 February 2019

Next earnings report:

27 February 2025

Last dividends:

N/A

Next dividends:

N/A
$368.23 M
-80%vs. 3y high
61%vs. sector
-vs. 3y high
-vs. sector
-45%vs. 3y high
69%vs. sector
-48%vs. 3y high
66%vs. sector

Price

after hours | 106 min ago
$3.76+$0.13(+3.66%)

Dividend

No data over the past 3 years
$15.34 M$16.80 M
$15.34 M-$42.22 M

Analysts recommendations

Institutional Ownership

ALEC Latest News

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital
globenewswire.com14 November 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $50 million.

Federman & Sherwood Investigates Abbott Laboratories Employees Credit Union (“ALEC”) for Data Breach
businesswire.com23 October 2024 Sentiment: NEGATIVE

OKLAHOMA CITY--(BUSINESS WIRE)-- #FedermanSherwood--Federman & Sherwood Investigates Abbott Laboratories Employees Credit Union (“ALEC”) for Data Breach.

Alector to Participate in Upcoming Healthcare Conferences
globenewswire.com29 August 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:

Alector, Inc. (ALEC) Q2 2024 Earnings Call Transcript
seekingalpha.com08 August 2024 Sentiment: POSITIVE

Alector, Inc. (NASDAQ:ALEC ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Katie Hogan – Senior Director-Corporate Communications and Investor Relations Arnon Rosenthal – Co-Founder and Chief Executive Officer Sara Kenkare-Mitra – President and Head-Research and Development Gary Romano – Chief Medical Officer Marc Grasso – Chief Financial Officer Conference Call Participants Michael Reid – Morgan Stanley Carter Gould – Barclays Tom Shrader – BTIG Sarah Schram – William Blair & Company Ananda Ghosh – H.C. Wainwright & Company Graig Suvannavejh – Mizuho Securities Corinne Jenkins – Goldman Sachs Operator Good afternoon, ladies and gentlemen, and welcome to the Alector Second Quarter and Midyear 2024 Earnings Conference Call.

Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates
zacks.com07 August 2024 Sentiment: NEUTRAL

Alector (ALEC) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to earnings of $0.02 per share a year ago.

Alector to Host Mid-Year Earnings Conference Call
globenewswire.com31 July 2024 Sentiment: NEUTRAL

Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
globenewswire.com28 July 2024 Sentiment: POSITIVE

--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer's disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative study population that enables testing of the effects of a novel TREM2 agonist in early AD--

Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform
globenewswire.com10 June 2024 Sentiment: POSITIVE

Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation

Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript
Seeking Alpha27 February 2024 Sentiment: POSITIVE

Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript

Strength Seen in Alector (ALEC): Can Its 6.0% Jump Turn into More Strength?
Zacks Investment Research08 February 2024 Sentiment: POSITIVE

Alector (ALEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

  • 1(current)

What type of business is Alector?

Alector, Inc. is a clinical-stage biopharmaceutical company that is developing ways to treat neurodegenerative diseases using expertise in neurology, immunology, and human genetics. Founded in 2013 with headquarters in South San Francisco. The company calls itself a pioneer in immuno-neurology - a new therapeutic approach to treating neurodegeneration that considers immune dysfunction as the root cause of many pathologies that drive degenerative brain diseases. The company is developing treatments that simultaneously counteract these pathologies and restore the brain's immune system. Alector has developed its own Discovery platform, which uses large sets of human genetic data, advanced tools in bioinformatics and visualization, and developments in neurodegeneration and immunology.

What sector is Alector in?

Alector is in the Healthcare sector

What industry is Alector in?

Alector is in the Biotechnology industry

What country is Alector from?

Alector is headquartered in United States

When did Alector go public?

Alector initial public offering (IPO) was on 07 February 2019

What is Alector website?

https://www.alector.com

Is Alector in the S&P 500?

No, Alector is not included in the S&P 500 index

Is Alector in the NASDAQ 100?

No, Alector is not included in the NASDAQ 100 index

Is Alector in the Dow Jones?

No, Alector is not included in the Dow Jones index

When was Alector the previous earnings report?

No data

When does Alector earnings report?

The next expected earnings date for Alector is 27 February 2025